TCR Therapy Market

Global TCR Therapy Market (2nd Edition): Distribution by Target Indication, Target Antigen, Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035

  • Lowest Price Guaranteed From USD 4,799

  • Pages
    363

  • View Count
    22316

T Cell Recepter Market Overview 

The TCR therapy market is estimated to be worth $0.03 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 51% during the forecast period, mainly driven by the need for targeted cancer treatment for solid tumors.

Modified T-cell receptor (TCR) based therapy is an emerging class of adoptive cell therapy that employs genetically modified lymphocytes to target specific tumor markers. Their tumor cell killing efficacy may be primarily attributed to the fact that they are pre-sensitized to cancer specific antigens; this enables such interventions to selectively target and eliminate tumor cells from the body of a host with negligible treatment-related side effects. Ongoing and planned clinical research initiatives in this direction are driven by encouraging results achieved in past trials, which were mostly focused on various hematological cancers and solid tumors. Driven by the ongoing pace of innovation in this field, sufficient financial support from investors and encouraging clinical trial results, the T cell receptor therapy market is likely to witness significant growth during the forecast period.

The image provides context of TCR therapy market. Given the recent approval of a TCR-based therapy, industry stakeholders have initiated several R&D efforts focused on evaluating the potential of such therapy candidates against various disease indications This image provides pipeline of T cell receptor therapies. More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders This image highlights t-cell receptor therapy market landscape. More than 90% of the therapy candidates, which are being developed to target a wide range of disease indications are autologous in nature; NY-ESO-1 and MAGE have emerged as the most popular target antigens

Key TCR Therapy Market Insights

The Global TCR Therapy Market (2nd Edition), 2022-2035: Distribution by Target Indication (Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, and Merkel Cell Cancer), Target Antigen (NY-ESO-1, EBV, gp100, and others), Key Players and Key Geographies (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2022-2035 report features an extensive study of the current market landscape, market size and future potential of TCR therapies. The market report highlights the efforts of several stakeholders engaged in this rapidly evolving segment of the biopharmaceutical industry. The report answers many key questions related to this market:

Need for T Cell Receptor Therapy for Cancer Treatment: Targeting the Unmet Need for Solid Tumors

Modified T cell receptor therapy, an upcoming class of cell-based interventions, is a promising therapeutic modality. TCR therapy is a novel segment within the T-cell therapy market, of which CAR T cell therapy is the biggest segment. Similar to other T-cell based interventions (such as CAR T cell therapy and tumor infiltrating lymphocytes), TCR therapies are designed to target the underlying causes (or primary mediators) of a clinical condition. All the approved CAR T cell therapies target hematological cancer; however, solid tumor treatment presents an opportunity area for the cell therapy developers. Additionally, this emerging class of biologics is believed to possess the potential to cater to unmet pharmacological needs across both oncological and non-oncological disorders, even those where small molecule drugs have proven to be inadequate. Although T cell receptor based immunotherapies are still considered an experimental approach, several clinical trials demonstrate the efficacy and therapeutic superiority of TCR therapies. The TCR therapy market growth will essentially be driven by their development for the high unmet needs in solid tumor treatment.

Current Market Landscape of T-Cell Receptor Therapies: Next Generation Engineered TCR T Cells Under Development

Presently, more than 100 industry and non-industry players across the globe are evaluating the potential of over 190 T cell receptor based immunotherapies for the treatment of various oncological and non-oncological disorders. It is worth highlighting that, in January 2022, the FDA approved the first TCR therapy, Kimmtrak® (Immunocore), for the treatment of adult patients with unresectable or metastatic uveal melanoma. More than 90% of the therapy candidates that are being developed to target a wide range of disease indications are autologous in nature. Only few of the candidates are allogeneic cell therapy. Further, NY-ESO-1 and MAGE emerged as the most popular target antigens in this industry. As per Adaptimmune, more than 84,000 patients annually die from MAGE-A4 positive tumors in the US and EU together. The company’s TCR T cell therapy targeting MAGE-A4, afami-cel, is expected to receive FDA approval for treatment of synovial sarcoma in 2024.

The TCR therapies market is also evolving with the companies working on development of next generation engineered TCR T cell therapies. Medigene is developing multiple TCR T cell therapies comprising of PD1-41BB switch receptor, helping the TCR therapies overcome challenges posed by the tumor microenvironment. Their therapies are currently in preclinical development. Such technological advancements will ensure development of safer and more efficacious T cell receptor therapies, driving the market growth during the forecast period.

The image provides a detailed clinical trial analysis of t-cell receptor therapies. In the last 10 years, close to 110  clinical trials have been registered across different geographies for the evaluation of TCR therapies; extensive efforts are underway to improve the successive generations of such therapies The image provides details on key opinion leaders in tcr therapy market. Close to 60 scientists from renowned universities are presently involved in the clinical development of TCR therapies; majority of these KOLs are primarily based in the US and China This image provides a list of TCR therapy manufacturers. Close to 200 players claim to have the required capabilities to manufacture different types of cell therapies; such firms also offer a wide range of services across different stages of product development

TCR Therapies Market Trends: Partnerships, Funding and Clinical Trials Analysis

The growing interest in this field is reflected in the notable increase in partnerships inked (close to 140 deals inked in the past decade; CAGR 23%) by several industry players and academic / research institutes. Big pharmaceutical companies are also entering the TCR therapy market through partnerships or M&A activity. In November 2022, AstraZeneca announced its plans to acquire TCR T cell therapy company Neogene Therapeutics for a sum of USD 320 million, which includes USD 200 million upfront payment of deal closure.

Additionally, various investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion across 140 instances, since 2007. Further, in the last 10 years, close to 110 clinical trials have been registered across different geographies for the evaluation of TCR therapies. MD Anderson is expected to begin a phase I clinical trial for its TCR NK cell therapy for advanced synovial sarcoma by the end of 2023. The T cell receptor therapy comprise cord-blood derived NK cells that express TCR against NY-ESO-1 antigen. The sponsor plans to enrol 44 patients for this clinical trial. Mostly driven by the need for effective treatment options for cancer, the TCR therapy pipeline is expected to steadily grow over the forecast period. Moreover, clinical success is likely to draw in investments that are likely to support the ongoing and anticipated therapy development initiatives. As the TCR companies move the products to clinical development, funding from big pharmaceutical companies and venture funding will support the market growth.

TCR Therapy Market Size: Asia-Pacific to Witness Highest Market Growth in this Emerging Segment of T-Cell Therapy Market

With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51% in the next decade. Specifically, in terms of target indication, the market is anticipated to be driven by nasopharyngeal carcinoma, multiple myeloma, and head and neck carcinoma. Additionally, more than 80% of the market is anticipated to be captured by players based in Europe and Asia-Pacific in 2035. Overall, we are led to believe that the global TCR-based therapy market is poised to witness significant growth in the foreseen future.

Key TCR Companies in the TCR Therapy Market

Examples of key companies engaged in the T cell therapy market (which have also been captured in this report) include Adaptimmune Therapeutics, Alaunos Therapeutics, blubird bio, Bristol Myers Squibb, Cellular Biomedicine Group, China Immunotech, Gilead Sciences, GlaxoSmithKline, Immatics, Immunocore, Intellia Therapeutics, Lion TCR, Takara Bio, TCRCure Biopharma, and Zelluna Immunotherapy. 

Recent Developments in TCR Therapy Market

Several recent developments have taken place in the field of TCR therapies. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.

  • In June 2023, Lion TCR announced the closing of USD 40 million in Series B2 funding round. 
  • In March 2023, Adaptimmune Therapeutics entered into a definitive agreement with TCR2 Therapeutics with an aim to create a preeminent cell therapy for the patients suffering from various types of solid tumors.
  • In January 2023, TScan Therapeutics announced the FDA clearance on its investigational new drug (IND) applications for T-Plex, TSC-204-A0201, and TSC-204-C0702 which is used for the treatment of solid tumors. 
The snapshot provides details on the level of partnerships activity in tcr therapy domain. A growing interest in this field is reflected from the increase in the partnership activity, involving both international and indigenous stakeholders; majority of the such deals were signed between players based in North America The image looks at the investor's interest in TCR therapies market. Several investors, having realized the opportunity within this upcoming segment of T-cell immunotherapy, have invested USD 11 billion, across 140 instances, since 2007 This infographic highlights TCR therapies market forecast. With a growing focus on the development pipeline and encouraging clinical results, the market is anticipated to witness an annualized growth rate of 51%, in the next decade

Scope of the TCR Therapy Market Report

The market reports presents an in-depth analysis of the various firms / organizations that are engaged in this industry, across different segments as defined in the below table:

Key Report Attributes Details

Base Year

2022

Forecast Period

2022 - 2035

CAGR

51%

Target Indications

Nasopharyngeal Carcinoma, Multiple Myeloma, Head and Neck Carcinoma, Sarcoma, Melanoma, Acute Myeloid Leukemia, Lung Cancer, Ovarian Cancer, Merkel Cell Cancer

Target Antigens

NY-ESO-1, EBV, gp100

Key Players

GlaxoSmithKline, China Immunotech, Xinqiao Hospital of Chongqing, TCRCure Biopharma, Adaptimmune Therapeutics, Immunocore, Intellia Therapeutics, Takara Bio, bluebird bio

Key Geographical Regions

North America, Europe, Asia-Pacific, Latin America, Middle East and North Africa (MENA), Rest of the World

Key Companies Profiled

Adaptimmune Therapeutics, Alaunos Therapeutics, Bristol Myers Squibb, Cellular Biomedicine, Gilead Biosciences, GlaxoSmithKline, Immatics, Immunocore, Lion TCR, Takara Bio, Zelluna Immunotherapy

Customization Scope 15% Free Customization Option
Powerpoint Presentation Complimentary
Excel Data Packs Complimentary: Market Landscape Analysis, Clinical Trial Analysis, KOL Analysis, Partnership and Collaboration Analysis, Funding and Investment Analysis, Patent Analysis, Market Forecast and Opportunity Analysis

Amongst other elements, the market report includes:

  • An executive summary of the insights captured during our research. It offers a high-level view on the current state of global market for TCR therapies and its likely evolution in the mid-long term.
  • A general overview of T cell receptor therapy in comparison to conventional forms of therapy that are being used for the treatment of various oncological indications. Further, it includes historical evolution of cancer immunotherapy, general manufacturing procedure of T-cell immunotherapies, and key attributes in development of TCR therapies
  • A detailed assessment of the overall TCR therapy market landscape, based on several relevant parameters, such as type of developer (industry and non-industry), phase of development (approved, phase II, phase I / II, phase I, and preclinical), therapeutic area (hematological cancer, solid tumor, and undisclosed), key target indication (lung cancer, melanoma, hepatocellular carcinoma, cervical cancer, ovarian cancer, sarcoma, breast cancer, gastric cancer, multiple myeloma, pancreatic cancer, acute myeloid leukemia, myelodysplastic syndrome, nasopharyngeal carcinoma, and others), key target antigen (NY-ESO-1, MAGE, HBV, PRAME, KRAS, EBV, HPV, Neoantigen, LAGE-1a, Meso, HLA, and others), source of T-cells (autologous / allogeneic), route of administration (intravenous and intratumoral), dosing frequency (single dose, multiple dose, and split dose), target patient segment (children, adults, and elderly patients), type of therapy (monotherapy and combination therapy) and most active players (in terms of number of TCR therapies). Further, the chapter also provides developer landscape of industry and non-industry players engaged in this market. 
  • A detailed analysis of popular target antigens, based on the number of TCR therapies that are being developed for a particular type of antigen by various industry stakeholders to identify potential targets.
  • An analysis of completed, ongoing, and planned clinical trials related to t-cell receptor therapy, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, target patient segment, type of sponsor / collaborator, most active players (in terms of number of registered trials), key focus areas and geography.
  • An insightful analysis highlighting the key opinion leaders (KOLs) in this industry, featuring an analysis of the various principal investigators of clinical trials related to TCR therapies, considering them to be KOLs, who are actively involved in R&D of t cell receptor therapies. In addition, it compares the relative expertise of KOLs based on a proprietary scoring criterion with that of a third party.
  • Elaborate profiles of marketed and mid- to late-stage clinical products (phase I/II or above); each profile features an overview of the therapy, its mechanism of action, dosage information, details on the cost and sales information (wherever available), a clinical development plan, and clinical trial results.
  • A detailed analysis of recent partnerships inked between several stakeholders engaged in TCR therapy market, covering R&D agreements, license agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements, clinical trial collaborations, product supply management agreements, joint ventures, and others.
  • An analysis of the funding and investments that have been made into companies having proprietary T-cell receptor candidates / technologies, including seed financing, venture capital financing, capital raised from IPOs and subsequent offerings, grants, and debt financing.
  • An in-depth analysis of patents related to TCR therapies, filed / granted till 2022, based on several relevant parameters, such as type of patent (granted, patent applications, and search reports), patent publication year, geographical distribution, Cooperative Patent Classification (CPC) symbols, emerging focus area, type of player, leading player (in terms of number of patents), and patent benchmarking. In addition, it features a patent valuation analysis, which evaluates the qualitative and quantitative aspects of the patents. 
  • A case study on manufacturing cell therapy products, highlighting the key challenges, and a detailed list of contract service providers and in-house manufacturers involved in this space.
  • An elaborate discussion on various factors that form the basis for the pricing of cell-based therapies. It features different models / approaches that a pharmaceutical company may choose to adopt to decide the price of a TCR therapy that is likely to be marketed in the coming years.
  • A review of the key promotional strategies that are being implemented by the developers of the approved TCR therapy (Kimmtrak®).
  • Elaborate profiles of the leading players in the TCR therapies market. Each company profile includes an overview of the developer and a brief description of the product portfolio specific to TCR therapies, the technology portfolio (if available), recent developments related to TCR therapies, and the manufacturing capabilities of the companies. Additionally, we have provided details of the strategic / venture capital investments made in these companies.

One of the key objectives of the market report was to estimate the current opportunity, market size and the future growth potential of TCR therapies over the forecast period. Based on several parameters, such as target consumer segments, region-specific adoption rates, and expected prices of such products, we have developed informed estimates of the likely evolution of the market over the forecast period 2022-2035. The market research report also includes likely sales forecasts of TCR therapies that are in the mid- to late stages of development. Additionally, it features market size projections for the overall TCR therapy market, wherein both the current and upcoming opportunity is segmented across target indication (nasopharyngeal carcinoma, multiple myeloma, head and neck carcinoma, sarcoma, melanoma, acute myeloid leukemia, lung cancer, ovarian cancer and merkel cell cancer), target antigen (NY-ESO-1, EBV, gp100 and others), key players and key geographical regions (North America, Europe, Asia Pacific, Latin America, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and add robustness to our model, we have provided three market forecast scenarios, namely the conservative, base, and optimistic scenarios, which represent different tracks of the industry’s evolution.

The opinions and insights presented in this market analysis were influenced by discussions conducted with several stakeholders in this industry. The market report features detailed transcripts of interviews held with the following individuals:

  • Former Vice President Immuno-Oncology, Small Company, Belgium
  • Former Vice President Scientific Affairs, Large Company, US
  • Former Co-Founder and Chief Executive Officer, Small Company, Singapore
  • Former Chief Operating Officer, Small Company, France

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Frequently Asked Questions

Question 1: What is TCR therapy?

Answer: TCR therapy is an emerging class of adoptive cell therapy that employs genetically modified lymphocytes to target specific tumor markers

Question 2: What is the growth rate of TCR therapy market?

Answer: The global TCR therapies market is expected to grow at a compound annual growth rate (CAGR) of 51% during the forecast period 2022-2035.

Question 3: Which region has the highest growth rate in the TCR Therapies market?

Answer: Asia Pacific is growing at the highest CAGR within the TCR Therapy market, over the forecast period 2022- 2035.

Question 4: How many players are developing TCR Therapies?

Answer: More than 100 industry and non-industry players are currently evaluating the potential of over 190 TCR-based immunotherapies for the treatment of various oncological and non-oncological disorders.

Question 5: Which target indication covers the largest TCR therapy market share?

Answer: Multiple myeloma, presently, captures the maximum market share (43%) of TCR therapy market in 2022. This market share is likely to decrease in the foreseen future as several promising leads are anticipated to be commercially launched over the coming decade.

Question 6: What is the partnership and collaboration trend in the TCR therapy market?

Answer: Currently, R&D agreements, licensing agreements, and product development and commercialization agreements are the common type of partnerships inked by developers involved in the TCR therapy market.

Question 7: What is the current IP landscape of TCR therapies?

Answer: Close to 76% of the filed patents were patent applications, while around 24% were granted patents and search reports. Of the total granted applications, close to 78% were filed in the US.

PRICING DETAILS

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print Read more about Single-User License

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple Read more about One Location Site License

This license grants the right of use of the purchased report by a department / team of individuals (up to 12) in a particular organization. The license does not limit the use to a particular site / office location. The report may be accessed on the computer Read more about Department License

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the Read more about Enterprise License

Discounts available for multiple report purchases
Click here to send an email to Roots Analysis team. sales@rootsanalysis.com